Stempeutron®-A novel, point of care Medical Device for addressing major unmet medical needs
Stempeutron® is an automated medical device for point-of-care isolation of therapeutic stem and stromal cells from aspirated fat/adipose tissue. Adipose tissue stroma is a rich source of mesenchymal stem cells and endothelial progenitor cells, as well as other tissue-building cells such as vascular smooth muscle cells, pericytes, pre-adipocytes, and fibroblasts. This cell cocktail, called the stromal vascular fraction (SVF), can give rise to new blood vessels, bone, cartilage, fat, and muscle among others. In recent years, researchers have established that SVF derived from fat tissue have clinical utility in the broad field of cell therapy and regenerative medicine for the repair of diseased organs. Stempeutron® provides a unique opportunity to isolate and concentrate SVF cells from a given volume of fat at the doctor’s clinic in a matter of hours for personalized therapeutic application.
Sector: Biotechnology, Pharmaceuticals
Country: India
Area of Application: Stempeutron® is a medical device intended for automated isolation of SVF cells from the patient’s own fat tissue at the point-of-care, with minimal manipulation and human intervention. The device will comprise of a hermetically sealed enclosure housing the mechanical and electronic components, within which the tissue processing will be carried out using sterile single-use disposables. Stempeutron® is designed to operate on a proprietary process and technology. The innovation in Stempeutron® lies in the concentration of clinical grade SVF cells without the use of a centrifuge, which is the conventional process for recovering the cells. This is achieved by using a proprietary filtration system. By eliminating centrifugation, the isolation becomes gentle, and the cost and footprint of the device is reduced.
Keywords: Stempeutron, SVF, Stem Cell
Advantages: Stempeutron® is a medical device intended for automated isolation of SVF cells from the patient’s own fat tissue at the point-of-care, with minimal manipulation and human intervention. The device will comprise of a hermetically sealed enclosure housing the mechanical and electronic components, within which the tissue processing will be carried out using sterile single-use disposables. Stempeutron® is designed to operate on a proprietary process and technology. The innovation in Stempeutron® lies in the concentration of clinical grade SVF cells without the use of a centrifuge, which is the conventional process for recovering the cells. This is achieved by using a proprietary filtration system. By eliminating centrifugation, the isolation becomes gentle, and the cost and footprint of the device is reduced.
Environmental aspects: Systems integration , Others
Development Status: Idea , Laboratory Model , Commercial Prototype , Design , Pilot Plant
Legal Protection: Trade Mark, Patent, Others
Technical specifications: The main operational modules required for digestion and filtration have been assembled into a fully automated alpha phase prototype device to generate proof-of-concept and confirm that the development of such a device is technically feasible. In this alpha prototype, we have tested the ability of the washing and digestion chamber to process fat tissue up to a volume of 500 ml. The phase separation to distinguish between the fatty and the aqueous fractions has also been accomplished by vertical positioning of the digestion chamber. The aqueous fraction obtained post digestion was loaded on to the filtration unit and the SVF cells were successfully recovered from the collection chamber. The SVF cells isolated from the device have been compared with the cells isolated by the manual process from the same fat tissue samples. Results obtained from the device have been found to be equivalent to the manual process in terms of SVF cell yield, viability and composition. The relative percentage of adipose tissue-derived stromal cells, endothelial and endothelial progenitor cells that are critical for tissue engraftment have also been found to be present in comparable numbers in the SVF obtained by the device and by the manual process. The biological function of these cells with respect to in vitro and in vivo angiogenesis is currently being determined. Taken together the data suggest that it is technically feasible to isolate SVF through this novel technology based device and proceed to the beta phase of building a completely automated and aseptic version of Stempeutron®.
Transfer Terms: Consultancy , Technical Services , Turnkey, Joint Venture , Equipment Supply , Subcontracting , Technology Licensing , Research Partnerships
Target Countries: Afghanistan, Aland Islands, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antarctica, Antigua And Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bonaire, Sint Eustatius and Saba, Bosnia And Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cape Verde, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chad, Channel Islands, Chile, China, Christmas Island, Cocos (keeling) Islands, Colombia, Comoros, Congo The Democratic Republic Of The, Congo, Cook Islands, Costa Rica, Cote D'ivoire, Croatia, Cuba, Curacao, Cyprus, Czech Republic, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Falkland Islands (malvinas), Faroe Islands, Fiji, Finland, France, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Germany, Ghana, Gibraltar, Greece, Greenland, Grenada, Guadeloupe, Guam, Guatemala, Guernsey, Guinea, Guinea-bissau, Guyana, Haiti, Heard Island And Mcdonald Islands, Holy See (vatican City State), Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iraq, Islamic Republic of Iran, Ireland, Ireland, Northern, Isle of Man, Israel, Italy, Cote D'ivoire, Jamaica, Japan, Jersey, Jordan, Kazakhstan, Kenya, Kiribati, Korea, Democratic People's Republic Of, Republic of Korea, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libyan Arab Jamahiriya, Liechtenstein, Lithuania, Luxembourg, Macau, Macedonia The Former Yugoslav Republic Of, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia Federated States Of, Moldova Republic Of, Monaco, Mongolia, Montenegro, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, Netherlands Antilles, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, Northern Mariana Islands, Norway, Oman, Pakistan, Palau, Palestinian Territory, Occupied, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Poland, Portugal, Puerto Rico, Qatar, Reunion, Romania, Russian Federation, Rwanda, Saba, Saipan, Saint Barthelemy, Saint Helena, Saint Kitts And Nevis, Saint Lucia, Saint Martin, Saint Pierre And Miquelon, Saint Vincent And The Grenadines, Samoa, San Marino, Sao Tome And Principe, Saudi Arabia, Scotland, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Sint Maarten (Dutch part), Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Georgia And The South Sandwich Islands, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Svalbard And Jan Mayen, Swaziland, Sweden, Switzerland, Syrian Arab Republic, Taiwan Province Of China, Tajikistan, Tanzania United Republic Of, Thailand, Timor-Leste, Togo, Tokelau, Tonga, Trinidad And Tobago, Tunisia, Turkey, Turkmenistan, Turks And Caicos Islands, Tuvalu, Uganda, United Kingdom, Ukraine, United Arab Emirates, UK of Great Britain & Northern Ireland (the), United States Minor Outlying Islands, United States, Uruguay, Uzbekistan, Vanuatu, Vatican City, Venezuela, Viet Nam, Virgin Islands British, Virgin Islands U.s., Wallis And Futuna, Western Sahara, Western Sahara, Yemen, Zaire, Zambia, Zimbabwe, World Wide
Estimated cost (US$): 1500000
Upload any relevant document:
Contact Person: ARAVIND K J
Address: Stempeutics Research Pvt. Ltd. 3rd Floor, Manipal Hospitals Whitefield, #143,EPIP Industrial Area, ITPL Main Road, Whitefield, Bangalore – 560048
City: Bangalore
Country: India
Zip/Pin Code: 560048

Contact Technology Provider